Kornimate/medical-research-clean huggingface dataset:
pharmacist-led treat-to-target urate lowering therapy in patients with gout

Conditions: Gout; Gouty Arthritis

Summary: this study will compare two different approaches to manage medications that lower uric acid levels. this study will be conducted at five va medical centers across the united states and will take 4-5 years to complete. individual participation will last up to two years.

this project will quantify and compare the effects of a pharmacist-led telehealth-delivered intervention versus usual care on arthritis flare burden and serum urate goal achievement in 310 u.s. veterans with gout enrolled from five va medical centers. the project will quantify the effects of the intervention on patient-reported outcomes (improvements in health-related quality of life, pain interference, and participant global assessment).

Eligibility criteria:
inclusion criteria: * us veterans over the age of 18 years with physician-diagnosed * documented hyperuricemia (su \>6.8 mg/dl) * satisfy acr/eular gout classification criteria * report 1 or more flares in the prior 6 months * receipt of a new ult prescription (allopurinol or febuxostat) initiated by a primary care provider or longer term ult but otherwise satisfy the flare/su criteria exclusion criteria: * any patient intolerant or unable to take ults (allopurinol or febuxostat) * patients with a rheumatology encounter within the prior 3 months
study of picibanil (ok432) sclerotherapy in children with macrocystic lymphatic malformations

Conditions: Lymphatic Malformations

Summary: objectives: i. determine the efficacy of picibanil sclerotherapy in children with macrocystic lymphangioma.

protocol outline: this is a multicenter study. patients are stratified according to prior treatment (no prior treatment vs prior surgical treatment) and geographic area. patients who meet all study criteria are put in the "immediate treatment group." patients receive an intralesional injection of picibanil (ok432) with the aid of ultrasonography or transillumination for localization of cysts. treatment repeats every 6-8 weeks for a total of up to 4 injections. after completion of treatment, patients are followed at 6 months, 1 year, and 2 years. completion date provided represents the completion date of the grant per oopd records

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * diagnosis of macrocystic lymphangioma of the head and/or neck cystic spaces at least 2.0 ml confirmed by radiographic imaging (mri or ct) mixed lymphangiomas (macrocystic and microcystic disease) allowed if macrocystic component comprises at least 50% of the total disease burden * no mixed hemangioma-lymphangioma lesions * at least 6 months since prior surgery for lymphangioma --patient characteristics-- * hematopoietic: no clinically significant hematologic disease no hemodynamic instability * hepatic: no clinically significant hepatic disorder * renal: no clinically significant renal disease no personal or family history of post-streptococcal glomerulonephritis * cardiovascular: no personal or family history of rheumatic heart disease * pulmonary: no respiratory failure other: * not pregnant or nursing * negative pregnancy test * no history of allergy to penicillin * no concurrent temperature of 100.5 degrees or greater * no active upper respiratory infection * no personal or family history of obsessive-compulsive or tic disorders * no personal or family history of panda (pediatric autoimmune neuro- psychiatric disorder associated with streptococcal infections) * no history of hypersensitivity to iodine, omnipaque, or gadolinium (if fluoroscopy is considered necessary) * no history of poor health (including congenital disorders, chronic diseases, or immunologic dysfunction)

Keywords: cystic hygroma lymphangiomas lymphatic malformations
oxycodone-naloxone in relieving opioid-related constipation

Conditions: Pain

Summary: the primary objective of this study is to demonstrate that subjects with moderate to severe non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone.

patients with a documented history of moderate to severe non-malignant pain that require around the clock opioid therapy will be randomised to an oxycodone or an oxycodone-naloxone treatment arm to assess the safety and efficacy of oxycodone/naloxone prolonged release compared to oxycodone prolonged-release in relieving opioid-related constipation.

Eligibility criteria:
inclusion criteria: * male or female subjects at lest 18 years or older with pain. * subjects must report constipation caused or aggravated by opioids. exclusion criteria: * females who are pregnant or lactating. * subjects with evidence of significant structural abnormalities of the gastrointestinal (gi) tract (e.g. bowel obstruction, strictures).

Keywords: a randomised double blind parallel group multicentre study to demonstrate improvement in symptoms of constipation in subjects with non malignant pain moderate to severe chronic non-malignant pain
association between functional changes in the brain and the perception of pain in patients with inflammatory bowel diseases (ibd) - measured with functional magnetic resonance imaging.

Conditions: Inflammatory Bowel Diseases

Summary: in the study the investigators aim to test whether transcranial direct current stimulation (tdcs)-induced pain reduction is in association with functional changes in the brain measured with functional magnetic resonance imaging (fmri) in patients with chronic inflammatory bowel diseases (ibd). hypothesis: transcranial direct current stimulation can reduce the perception of pain in patients with chronic inflammatory bowel diseases, which is in association with changes in the brain measured via fmri.


Eligibility criteria:
inclusion criteria: * inflammatory bowel disease * chronic pain (more than 3 months) * pain (vas \> 3/10) exclusion criteria: * contraindication to transcranial direct current stimulation * contraindications to functional magnetic resonance imaging (fmri) * pregnancy * sever internal or psychiatric condition
cost/effectiveness analysis of the respiratory poligraphy at home

Conditions: Suspected Sleep Apnea; Daytime Sleepiness

Summary: the abbreviated diagnostic sleep studies (rp), made at home and transferred telematically to the sleep laboratory, are useful for the diagnosis of sleep apnea and due to a lower cost, it could be an alternative to conventional polysomnography. objectives: 1) usefulness of domiciliary study evaluated by percentage of patients diagnosed of sahs compared with psg and agreement in the therapeutic decision. 2) direct costs of patients included in the study. design: controlled, randomized, crossed and blind (320 patients) comparing pr made at home with psg, in patients suspicious of sahs. the equipment transfer will be made by a transport agency from home to home in order to be universal the access to this diagnostic model. the file transmission with the raw data of the study will be made telematically by gprs. if the aims of the study reach an end there will be a considerable change in the clinical practice making possible the international acceptation of domiciliary pr as diagnosis of sahs and adapting the diagnosis of this syndrome to the new technologies of communication. the universalization of domiciliary pr would make possible that the diagnosis of sahs could be done in any patient and in any country with gprs technology and a transport agency, that is to say in all developed countries. as sleep apneas affect 5-7 million persons in spain and there is association between sleep apneas and cardiovascular risk, in the immediate future we must evaluate this disease as we do today with the cholesterol determination. if our results are as predicted, the primary care physician could start and in a lot of cases finish the sahs diagnostic process. this would simplify remarkably the diagnosis of sahs and would alleviate a lot the process cost all over the world.


Eligibility criteria:
inclusion criteria: 1. age between 18 and 70 years. 2. without clinical suspicion referred to any other sleep pathology susceptible of presenting daytime sleepiness. 3. living 20 km or more far from the hospital participating in the study. exclusion criteria: 1. psychophysical incapacity to answer questionnaires. 2. patients who do not get pass the proof of placing the pr (see below). 3. patients who present restrictive chronic disease previously diagnosed (neoplasy, any origin chronic pain, renal failure, severe chronic obstructive pulmonary disease and any other limited chronic disease) 4. structural cardiopaty or coronary documented non controlled by means of medical treatment . 5. toxicomanies. alcoholism (more than 80 gr/day in men and 60 gr/day in women. 6. informed consent not obtained.
4 repeat tauopathy neuroimaging initiative

Conditions: Progressive Supranuclear Palsy; Corticobasal Degeneration

Summary: the purpose of this study is to evaluate several different tests, including brain imaging, eye movement testing, body fluid samples, measurements of memory and other thinking abilities, and measures of functional independence in the hope that this information can be used to guide diagnosis and treatment of psp and cbd in the future. recent advances in our understanding of the biological causes of these diseases offer hope for new treatments. as such treatments are developed, sensitive and specific biological measurements (biomarkers) will be needed to provide precise and direct measures of the state of the brain, which will improve the statistical power of clinical trials. brain imaging with magnetic resonance imaging (mri) has previously been used to measure disease-related changes in the brain. the goal of this study is to identify the best methods of analysis (including eye movements, imaging, and behavioral measures) for tracking psp and cbd over time. in addition, certain biomarkers in the blood and cerebrospinal fluid might also be useful for following these diseases over time. this study will examine the value of blood and csf biomarkers relative to brain imaging and functional measures.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of progressive supranuclear palsy or corticobasal degeneration * must have a reliable study partner who has frequent contact with the subject * willing and able to undergo testing procedures exclusion criteria: * significant neurological disease other than psp or cbd * presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body

Keywords: progressive supranuclear palsy corticobasal degeneration biomarker neuroimaging mri tau oculomotor
detection of upper gastrointestinal (gi) bleeding using a novel bleeding sensor capsule -healthy volunteers study

Conditions: Upper Gastrointestinal Bleeding

Summary: the objective of the investigation is to evaluate the feasibility of detecting blood in healthy volunteers after ingestion of autologous blood mixed with water.

a total of 10 healthy volunteers were recruited to undergo a testing procedure. subjects were instructed to ingest the pillsense capsule with 100ml of water. the position of the capsule in the stomach was verified by fluoroscopy. subjects were then asked to sequentially drink (every 5min) 2 mixtures containing 25ml of water and 25ml of their own blood obtained from a peripheral vein. the pillsense result ("blood detected" or " blood not detected") was recorded on clinical report form after 5 minutes from capsule ingestion and after 5 minutes from the ingestion of both mixtures containing blood. subjects were followed-up for capsule passing.

Eligibility criteria:
inclusion criteria: 1. age 18 -60 years 2. ability to give written informed consent exclusion criteria: 1. circulatory or hemodynamic instability with a clear need for urgent endoscopy or surgery (systolic blood pressure \ 100 / min) 2. known current stenosis of the gi tract 3. presence of pacemaker or other implantable electronic device 4. dysphagia or difficulties in swallowing pills the size of the capsule 5. history of achalasia or known esophageal dysmotility 6. history of gastroparesis 7. history of severe constipation (1 bowel movement per week or less) 8. healthy volunteers who are currently pregnant or breastfeeding, or intend to become pregnant during the investigation 9. active psychological issues preventing participation 10. stomach bezoar 11. history of severe esophagitis 12. history of crohn disease 13. history of diverticulitis 14. history of bowel obstruction 15. suspected gastrointestinal tumor disease 16. planned mri investigation (mri needed before the capsule is excreted)
electrophysiological characteristics and anatomical differentiation of epileptic and non-epileptic myoclonus.

Conditions: Myoclonus; Evoked Potential

Summary: this study was conducted on a series of patients with myoclonus to identify the electrophysiological characteristics and the anatomical classification of myoclonus of different causes.

the current study included 50 patients with different types of myoclonus in comparison to 30 control subjects. electrophysiological study was done for all patients by somatosensory evoked potential (ssep) and electroencephalography (eeg) while the control group underwent ssep. ssep was studied in the patients and control group by stimulation of right and left median nerves.

Eligibility criteria:
inclusion criteria: * myoclonus classified into primary and secondary myoclonus. exclusion criteria: * psychiatric comorbidity to exclude psychological myoclonus.

Keywords: myoclonus, evoked potential
a comparator study of a tasso device blood sample to traditional venous blood sample for cbc

Conditions: Leukopenia; Leukocytosis; Neutropenia

Summary: this study will evaluate the feasibility of using capillary blood samples collected with the tasso device for analysis of cbc in diseased patients with leukemia, lymphoma, and/or other blood cell disorders. this investigation will include a minimum of 40 sample sets from unique patients.

this study will evaluate the feasibility of using capillary blood samples collected with the tasso device for analysis of cbc in diseased patients with leukemia, lymphoma, and/or other blood cell disorders. this investigation will include a minimum of 40 sample sets from unique patients. the primary aim of this study is to demonstrate the agreement between capillary blood collected using the tasso device and venous blood collected in a k2edta (dipotassium ethylenediaminetetraacetic acid) tube according to established sampling procedures for quantification of wbc and anc as part of a standard cbc panel with 5-part differential. the secondary aim of the study is to demonstrate the agreement between tasso device and venous samples for the measurement of additional analytes evaluated as part of a standard cbc panel with 5-part differential, including plts, hgb, rbc, hct, mcv, lymphocytes, monocytes, eosinophils, and basophils. an exploratory aim of this research is to evaluate patient acceptance of the tasso device in a diseased population. adverse events (aes) occurring up to 24 hours after use of the tasso device will be evaluated. patient response to using the tasso device will be collected via simple survey.

Eligibility criteria:
inclusion criteria: 1. willing and able to provide written (or electronic) informed consent prior to study entry 2. at least 18 years of age 3. requiring a cbc blood test as part of the patient's standard of care 4. have abnormal laboratory results of either leukopenia, leukocytosis or neutropenia. 5. normal skin integrity and healthy skin appearance around the capillary collection site (upper arm/shoulder area on at least one side) exclusion criteria: 1. unable to give full and free consent to participate in a study due to limited capacity or risk of undue influence or coercion (including but not limited to children, prisoners, individuals with diminished decision-making capacity, illiterate or educationally disadvantaged populations) or any other individual who is unable to give full and free consent in the judgement of the investigator 2. at the determination of the treating physician, unsuitable for enrollment due to severe immunocompromised status or other comorbidities.

Keywords: leukocytosis neutropenia leukopenia cbc tasso
rapa-keloid study of keloid regression

Conditions: Keloid

Summary: 1. to test whether topical rapamycin regresses established keloids in humans by measuring surface area and height changes in the scar over time (6 months) 2. to test safety of product and feasibility of conduct for future clinical trial

this pilot trial will use daily 0.5-1.0 ml applications of 8% rapa (rapamycin) in a petrolatum vehicle to treat established keloid lesions in 5 persons with at least 2 chronic keloids in similar body regions (greater than 1-year duration). treatment will be applied once daily for 6 months. one keloid will receive 8% rapa ointment and the other keloid will receive petrolatum-only ointment as a control. surface areas and height of keloids will be monitored pre- and post-treatment to evaluate responses. keloid surface area and height changes will be measured pre-treatment and thereafter on a monthly basis using standardized digital photography with a tripod-mounted 8mp canon s5is camera and calipers to measure keloid height (37). surface areas of all photographed lesions will be measured with image j (http://rsbweb.nih.gov/ij/index.html), a public image-processing program that was used to analyze preliminary data and this study will use the same approach.

Eligibility criteria:
inclusion criteria: * subject must have at least 2 keloid scars (for at least 1 year) in similar body locations that are easy to reach to apply ointment to * subject will be in good health with all chronic diseases (such as hypertension, coronary artery disease, etc.) clinically stable * cognitive functioning sufficient to provide informed consent * physically able to apply ointment to keloids daily * able to attend monthly clinic visits for 6 months exclusion criteria: * diagnosis of diabetes * subjects taking the following medications: systemic steroid or immunosuppressant therapy within the past 6 months * local area steroidal treatment within the past 3 months * history of allergy to rapamycin of petrolatum-based products
efficacy of eye movement desensitization & reprocessing vs cognitive behavioral therapy in post-traumatic stress and comorbid disorders in pakistan

Conditions: Post Traumatic Stress Disorder; Depression, Anxiety

Summary: this randomized controlled trial will check the efficacy of eye movement desensitization \& reprocessing vs cognitive behavioral therapy in post-traumatic stress and comorbid disorders in pakistan

this randomized controlled trial will check the efficacy of eye movement desensitization \& reprocessing vs cognitive behavioral therapy in post-traumatic stress and comorbid disorders in pakistan. it will be a single blind multi-center rct with two arms (emdr and cbt). this study will broadly work on following aims: 1. initially the comparative efficacy of emdr and cbt (i.e., standard face-to-face protcols) will be determined on large scale in pakistan by: 1. examining whether emdr is non-inferior to cbt in the treatment of ptsd and its two comorbidities in pakistan. 2. studying changes in the symptoms (i.e., reduction in the ptsd and comorbid symptoms with the passage of time) after administering emdr and cbt. the level of change in the symptoms will ultimately help in determining the extent of effectiveness of both therapies. 3. examine the reciprocal relationship between ptsd and comorbid symptoms for knowing whether any reduction in the ptsd symptoms can help in reducing the comorbid symptoms after administering emdr and cbt. 2. at the mean time work on the design and development of virtual emdr and cbt therapies (i.e., web-based and mobile applications) will also be started. the initial prototypes will be tested for its comparative efficacy. later once the final versions will be developed then it will be also tested for its comparative efficacy on large scale in pakistan.

Eligibility criteria:
inclusion criteria: reverse of the exclusion critera exclusion criteria: the following patients will be excluded: 1. patients below the age of 15 years and above 60 years, since this study is neither on children nor on old aged patients; 2. patients who can't move their hands and eyes/or can't perform basic movements; 3. patients who are unconscious for longer periods and unable to recover consciousness; 4. patients not meeting the basic screening criteria of ptsd/ ptsd is not the main problem; 5. patients with severe intellectual impairments, since such patients are difficult to communicate

Keywords: post traumatic stress disorder emdr cbt pakistan
molecular mechanisms leading to chemoresistance in epithelial ovarian cancer

Conditions: Ovarian Cancer

Summary: epithelial ovarian cancer is the most lethal gynecological malignancy in developed countries and the fifth most common cause of cancer-related death in women. poor prognosis is due to challenges in early diagnosis and development of inevitable resistance to chemotherapy in majority of patients despite of good initial treatment response. the purpose of this prospective study is to analyze variation in microrna expression in prediction of primary treatment response and the role of micrornas in development of chemoresistance in epithelial ovarian cancer. • objectives: to screen micrornas from prospectively collected plasma, urine and tumor samples from patients diagnosed with epithelial ovarian cancer. samples are analyzed for microrna expression and differential expression is correlated with primary treatment response, progression-free survival and overall survival. • methods: plasma, urine and tumor samples are collected at primary surgery (open surgery or diagnostic laparoscopy) or interval debulking surgery, at 1st, 3rd and 6th neoadjuvant or adjuvant chemotherapy and at progression for high-throughput screening of microrna expression by array technology.

inclusion criteria: patients operated for a suspected ovarian malignancy in the department of obstetrics and gynecology in tampere university informed consent obtained

Eligibility criteria:
inclusion criteria: * 18 years of age, informed consent. exclusion criteria: * informed consent not provided, age under 18 years.

Keywords: chemoresistance mirna microrna
effect of the paincoach app on pain and opiate use after total knee replacement

Conditions: Total Knee Replacement; Pain; Opioid Use; E-health App

Summary: less is known about pain and opiate use at home directly after total knee replacement (tkr). regarding side effects, low opiate use is desired. an e-health application, paincoach app, was developed to guide patients in pain control and opiate use. the aim of this study was to investigate the effect of the paincoach app on pain and opiate use in tkr patients in the first two weeks at home after surgery. the hypothesis was that the use of this app would decrease pain and opiate use.


Eligibility criteria:
inclusion criteria: * planned for primary tkr exclusion criteria: * no possession of a smartphone or tablet * contra-indication to any of the pain medication used in the study * no email address * no internet at home * no thorough command of the dutch language * suffering from memory disorders * surgery under general anaesthesia